
Sign up to save your podcasts
Or
It's estimated only one percent of medical research spending globally goes toward female-specific conditions that aren't related to cancer. But even as underfunding of women's health persists -- companies focused on women's health are innovating. Dr. Sara Naseri is working to reframe menstrual blood as a diagnostic tool rather than waste, with her company called Qvin. It received FDA clearance in January of this year for a new kind of blood test: a diagnostic menstrual pad.
Guests: Dr. Sara Naseri, CEO and co-founder of Qvin; Axios' Adriel Bettelheim
Credits: 1 big thing is produced by Niala Boodhoo, Alexandra Botti, and Jay Cowit. Music is composed by Alex Sugiura and Jay Cowit. You can reach us at [email protected]. You can send questions, comments and story ideas as a text or voice memo to Niala at 202-918-4893.
4.4
20222,022 ratings
It's estimated only one percent of medical research spending globally goes toward female-specific conditions that aren't related to cancer. But even as underfunding of women's health persists -- companies focused on women's health are innovating. Dr. Sara Naseri is working to reframe menstrual blood as a diagnostic tool rather than waste, with her company called Qvin. It received FDA clearance in January of this year for a new kind of blood test: a diagnostic menstrual pad.
Guests: Dr. Sara Naseri, CEO and co-founder of Qvin; Axios' Adriel Bettelheim
Credits: 1 big thing is produced by Niala Boodhoo, Alexandra Botti, and Jay Cowit. Music is composed by Alex Sugiura and Jay Cowit. You can reach us at [email protected]. You can send questions, comments and story ideas as a text or voice memo to Niala at 202-918-4893.
38,148 Listeners
7,604 Listeners
6,653 Listeners
25,838 Listeners
10,687 Listeners
1,520 Listeners
86,581 Listeners
4,525 Listeners
111,562 Listeners
2,304 Listeners
32,384 Listeners
10,107 Listeners
6,751 Listeners
5,420 Listeners
15,174 Listeners
4,367 Listeners